NCT04628338View on ClinicalTrials.gov

IFN-γ to Treat Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) That Has Relapsed After Allogeneic Hematopoietic Stem Cell Transplantation

EARLY_PHASE1CompletedINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

March 8, 2021

Primary Completion Date

October 30, 2023

Study Completion Date

October 30, 2023

Conditions
Myelodysplastic SyndromesMyeloid LeukemiaAllogeneic Stem Cell Transplantation
Interventions
DRUG

IFN-γ (interferon gamma-1b) injection

Dosage form: 100 mcg (2 million International Units) per 0.5 mL solution, administered subcutaneously Dose regimen: three times weekly (Weeks 0-7), once weekly (Weeks 8-12)

Trial Locations (1)

15232

UPMC Hillman Cancer Center, Pittsburgh

All Listed Sponsors
collaborator

Horizon Pharma USA, Inc.

INDUSTRY

lead

Sawa Ito, MD

OTHER

NCT04628338 - IFN-γ to Treat Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) That Has Relapsed After Allogeneic Hematopoietic Stem Cell Transplantation | Biotech Hunter | Biotech Hunter